tyb
that is what I though when departure was posted lb. safest place that one.
==Top insider sale/buy of the week: Crowdstrike sold by Warburg Pincus: $353.70m and Immunomedics Inc, bought by Avoro Capital Advisors: $35m-Dec 5 (Dec 9 filing)
What Is CrowdStrike, the Company Trump Mentioned During His Ukraine Call?
The "transcript" of President Donald Trump’s call with Ukrainian President Volodymyr Zelensky has been released, and there are more questions than it answers. One such question is Trump’s reference to CrowdStrike. According to the White House’s memo, Trump said, “I would like you to do us a favor though because our country has been through a lot and Ukraine knows a lot about it. I would like you to find out what happened with this whole situation with Ukraine, they say Crowdstrike…”
“I guess you have one of your wealthy people… The server, they say Ukraine has it,” the memo continues. “There are a lot of things that went on, the whole situation. I think you’re surrounding yourself with some of the same people.”
CrowdStrike is a U.S.-based internet security company that was hired to investigate the hack of the Democratic National Committee’s servers in 2016. It defines itself as a “cloud-native endpoint protection platform built to stop breaches.” The company determined at the time that two groups affiliated with the Russian government were responsible for the attack.
rest at link
https://fortune.com/2019/09/25/what-is-crowdstrike-trump-ukraine-call-transcript-memo/
Immunomedics
Immunomedics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing monoclonal antibody-based products for the targeted treatment of cancer. Its technologies allow it to create humanized antibodies that can be used either alone in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins. It has a pipeline of six clinical-stage product candidates. Its portfolio of investigational products includes antibody-drug conjugates (ADCs) that are designed to deliver a payload of a chemotherapeutic directly to the tumor, while the managing overall toxic effects that are found with conventional administration of these chemotherapy agents. Its ADCs are sacituzumab govitecan (IMMU-132) and labetuzumab govitecan (IMMU-130). The Company also has a range of other product candidates that target solid tumors and hematologic malignancies, as well as other diseases, in various-stages of clinical and pre-clinical development.
Number of employees : 346 people.
secondary via Goldman Sachs and BofA
IMMUNOMEDICS INC : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K)
https://www.marketscreener.com/IMMUNOMEDICS-INC-9671/news/IMMUNOMEDICS-INC-Entry-into-a-Material-Definitive-Agreement-Other-Events-Financial-Statements-an-29703145/
https://www.marketscreener.com/IMMUNOMEDICS-INC-9671/company/
https://www.finviz.com/insidertrading.ashx?oc=1414565&tc=2&b=2
https://www.finviz.com/insidertrading.ashx?oc=1633313&tc=1&b=2